|
1
|
Li Z, Zhang P, Yan A, Guo Z, Ban Y, Li J,
Chen S, Yang H, He Y, Li J, et al: ASXL1 interacts with the cohesin
complex to maintain chromatid separation and gene expression for
normal hematopoiesis. Sci Adv. 3:e16016022017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Szilvassy SJ: The biology of hematopoietic
stem cells. Arch Med Res. 34:446–460. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pui CH: Acute lymphoblastic
leukemiaChildhood Leukemias. 3rd. Cambridge University Press;
Cambridge: pp. 332–366. 2012, View Article : Google Scholar
|
|
4
|
Collins L, Beaumont L, Cranston A, Savoie
S, Nayiager T and Barr R: Anthropometry in long-term survivors of
acute lymphoblastic leukemia in childhood and adolescence. J
Adolesc Young Adult Oncol. Jan 24–2017.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
El-Rifai W, Ruutu T, Elonen E, Volin L and
Knuutila S: Prognostic value of metaphase-fluorescence in situ
hybridization in follow-up of patients with acute myeloid leukemia
in remission. Blood. 89:3330–3334. 1997.PubMed/NCBI
|
|
6
|
Onciu M and Pui CH: Diagnosis and
classificationChildhood Leukemias. Pui CH: 3rd. Cambridge
University Press; Cambridge: pp. 21–48. 2012, View Article : Google Scholar
|
|
7
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rodriguez-Galindo C, Friedrich P,
Morrissey L and Frazier L: Global challenges in pediatric oncology.
Curr Opin Pediatr. 25:3–15. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): a population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Creutzig U, Büchner T, Sauerland MC,
Zimmermann M, Reinhardt D, Döhner H and Schlenk RF: Significance of
age in acute myeloid leukemia patients younger than 30 years: a
common analysis of the pediatric trials AML-BFM 93/98 and the adult
trials AMLCG 92/99 and AMLSG HD93/98A. Cancer. 112:562–571. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deschler B and Lübbert M: Acute myeloid
leukemia: epidemiology and etiology. Cancer. 107:2099–2107. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pui CH, Robison LL and Look AT: Acute
lymphoblastic leukaemia. Lancet. 371:1030–1043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pui CH: Acute lymphoblastic leukemia:
introduction. Semin Hematol. 46:1–2. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pui CH, Carroll WL, Meshinchi S and Arceci
RJ: Biology, risk stratification, and therapy of pediatric acute
leukemias: an update. J Clin Oncol. 29:551–565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pui CH, Mullighan CG, Evans WE and Relling
MV: Pediatric acute lymphoblastic leukemia: where are we going and
how do we get there? Blood. 120:1165–1174. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goulden NJ, Knechtli CJ, Garland RJ,
Langlands K, Hancock JP, Potter MN, Steward CG and Oakhill A:
Minimal residual disease analysis for the prediction of relapse in
children with standard-risk acute lymphoblastic leukaemia. Br J
Haematol. 100:235–244. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Veerman AJ, Kamps WA, van den Berg H, van
den Berg E, Bökkerink JP, Bruin MC, van den Heuvel-Eibrink MM,
Korbijn CM, Korthof ET, van der Pal K, et al: Dutch Childhood
Oncology Group: Dexamethasone-based therapy for childhood acute
lymphoblastic leukaemia: results of the prospective Dutch Childhood
Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol.
10:957–966. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schrappe M, Hunger SP, Pui CH, Saha V,
Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, et
al: Outcomes after induction failure in childhood acute
lymphoblastic leukemia. N Engl J Med. 366:1371–1381. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Balduzzi A, Valsecchi MG, Uderzo C, de
Lorenzo P, Klingebiel T, Peters C, Stary J, Felice MS, Magyarosy E,
Conter V, et al: Chemotherapy versus allogeneic transplantation for
very-high-risk childhood acute lymphoblastic leukaemia in first
complete remission: comparison by genetic randomisation in an
international prospective study. Lancet. 366:635–642. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bleyer A, Budd T and Montello M:
Adolescents and young adults with cancer: the scope of the problem
and criticality of clinical trials. Cancer. 107 Suppl:1645–1655.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nachman J: Clinical characteristics,
biologic features and outcome for young adult patients with acute
lymphoblastic leukaemia. Br J Haematol. 130:166–173. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bhojwani D, Pei D, Sandlund JT, Jeha S,
Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff S, Onciu M, Cheng C,
et al: ETV6-RUNX1-positive childhood acute lymphoblastic leukemia:
improved outcome with contemporary therapy. Leukemia. 26:265–270.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maloney KW, Carroll WL, Carroll AJ,
Devidas M, Borowitz MJ, Martin PL, Pullen J, Whitlock JA, Willman
CL, Winick NJ, et al: Down syndrome childhood acute lymphoblastic
leukemia has a unique spectrum of sentinel cytogenetic lesions that
influences treatment outcome: a report from the Childrens Oncology
Group. Blood. 116:1045–1050. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hunger SP, Loh ML, Whitlock JA, Winick NJ,
Carroll WL, Devidas M and Raetz EA: COG Acute Lymphoblastic
Leukemia Committee: Childrens Oncology Groups 2013 blueprint for
research: acute lymphoblastic leukemia. Pediatr Blood Cancer.
60:957–963. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nachman JB, La MK, Hunger SP, Heerema NA,
Gaynon PS, Hastings C, Mattano LA Jr, Sather H, Devidas M, Freyer
DR, et al: Young adults with acute lymphoblastic leukemia have an
excellent outcome with chemotherapy alone and benefit from
intensive postinduction treatment: a report from the Childrens
Oncology Group. J Clin Oncol. 27:5189–5194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stock W, Luger S, Advani A, Geyer S,
Harvey R, Mullighan C, Willman CL, Malnassy G, Parker E, Laumann
KM, et al: Favorable outcomes for older adolescents and young
adults (AYA) with acute lymphoblastic leukemia (ALL): early results
of US intergroup trial C10403. Blood. 124:7962014.
|
|
27
|
Larsen EC, Salzer W, Nachman J, Devidas M,
Freyer DR, Raetz EA, Winick N, Hunger SP and Carroll WL: Treatment
toxicity in adolescents and young adult (AYA) patients compared
with younger patients treated for high risk B-precursor acute
lymphoblastic leukemia (HR-ALL): a report from the Childrens
Oncology Group study AALL0232. Blood. 118:15102011.
|
|
28
|
Carlson RH: Renewed calls for adolescents
and young adults with ALL to be treated with pediatric protocols.
Oncol Times. 37:20–21. 2015. View Article : Google Scholar
|
|
29
|
Advani AS, Hunger SP and Burnett AK: Acute
leukemia in adolescents and young adults. Semin Oncol. 36:213–226.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gramatges MM and Rabin KR: The adolescent
and young adult with cancer: state of the art - acute leukemias.
Curr Oncol Rep. 15:317–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nguyen K, Devidas M, Cheng SC, La M, Raetz
EA, Carroll WL, Winick NJ, Hunger SP, Gaynon PS and Loh ML;
Childrens Oncology Group, : Factors influencing survival after
relapse from acute lymphoblastic leukemia: a Childrens Oncology
Group study. Leukemia. 22:2142–2150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
DeAngelo DJ: The use of novel monoclonal
antibodies in the treatment of acute lymphoblastic leukemia.
Hematology Am Soc Hematol Educ Program. 2015:400–405.
2015.PubMed/NCBI
|
|
33
|
Rubnitz JE, Inaba H, Dahl G, Ribeiro RC,
Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, et al:
Minimal residual disease-directed therapy for childhood acute
myeloid leukaemia: results of the AML02 multicentre trial. Lancet
Oncol. 11:543–552. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mullighan C, Hunger SP and Meshinchi S:
Molecular genetics in children, adolescents and young adults with
acute lymphoblastic leukemia and acute myeloid
leukemiaHematological Malignancies in Children, Adolescents and
Young Adults. Cairo MS and Perkins SL: World Scientific Publishing
Co. Pte. Ltd.; Singapore: pp. 121–142. 2012, View Article : Google Scholar
|
|
35
|
Pratz KW, Sato T, Murphy KM, Stine A,
Rajkhowa T and Levis M: FLT3-mutant allelic burden and clinical
status are predictive of response to FLT3 inhibitors in AML. Blood.
115:1425–1432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Balgobind BV, Raimondi SC, Harbott J,
Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M,
Creutzig U, Dworzak MN, et al: Novel prognostic subgroups in
childhood 11q23/MLL-rearranged acute myeloid leukemia: results of
an international retrospective study. Blood. 114:2489–2496. 2009.
View Article : Google Scholar : PubMed/NCBI
|
